Explore the details of the Janssen Pharmaceuticals, Inc. V. Hikma Pharmaceuticals Usa Inc. case under case number 1:23-cv-00595 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00595
Filing Date
May 31, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Janssen Pharmaceutica NV -
Hikma Pharmaceuticals USA Inc. -
West-Ward Columbus Inc. -

Patents Involved in the Case

This case involves 4 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US11446260B2
-US11173134B2
-US10869844B2
-US11311500B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

May 31, 2023Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 06/01/2023)PACER Document
May 31, 2023COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Hikma Pharmaceuticals PLC, Hikma Pharmaceuticals USA Inc., West-Ward Columbus Inc. ( Filing fee $ 402, receipt number ADEDC-4148282.) - filed by Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV. (Attachments: # 1 Exhibit A-D, # 2 Civil Cover Sheet) (vfm) (Entered: 06/01/2023)PACER Document
May 31, 2023Summons Issued as to Hikma Pharmaceuticals PLC on 5/31/2023; Hikma Pharmaceuticals USA Inc. on 5/31/2023; West-Ward Columbus Inc. on 5/31/2023. (Attachments: # 1 Summons Issued, # 2 Summons Issued) (vfm) (Entered: 06/01/2023)PACER Document
May 31, 2023Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceutica NV, Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceutica NV, Janssen Pharmaceuticals, Inc.. (vfm) (Entered: 06/01/2023)PACER Document
May 31, 2023Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,869,844 B2 ;11,173,134 B2 ;11,311,500 B2 ;11,446,260 B2. (vfm) (Entered: 06/01/2023)PACER Document
May 31, 2023Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 04/19/2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 9/5/2026. (vfm) (Entered: 06/01/2023)PACER Document